v3.25.3

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses
Research and development	$ 13,742	$ 20,178	$ 46,769	$ 50,337
General and administrative	5,613	6,326	18,340	17,897
Total operating expenses	19,355	26,504	65,109	68,234
Loss from operations	(19,355)	(26,504)	(65,109)	(68,234)
Other (expense) income
Currency exchange gain (loss), net	98	1,630	(381)	1,078
Interest income	255	1,068	954	3,996
Interest expense	(886)	0	(1,139)	0
Change in fair value of warrants (Note 3)	9,846	0	7,259	0
Total other income (expense), net	9,313	2,698	6,693	5,074
Loss before income tax expense (credit)	(10,042)	(23,806)	(58,416)	(63,160)
Income tax (credit) expense	(1,664)	209	(1,400)	998
Net loss	(8,378)	(24,015)	(57,016)	(64,158)
Net loss attributable to common shareholders	$ (8,378)	$ (24,015)	$ (57,016)	$ (64,158)
Net loss per common share, basic	$ (0.13)	$ (0.36)	$ (0.86)	$ (0.97)
Net loss per common share, diluted	$ (0.13)	$ (0.36)	$ (0.86)	$ (0.97)
Weighted-average number of shares used in computing net loss per common share, basic	66,941,964	65,880,914	66,238,484	65,880,914
Weighted-average number of shares used in computing net loss per common share, diluted	66,941,964	65,880,914	66,238,484	65,880,914
Other comprehensive loss
Net Income (Loss)	$ (8,378)	$ (24,015)	$ (57,016)	$ (64,158)
Foreign currency translation	(353)	(1,374)	(314)	(1,331)
Total comprehensive loss	$ (8,731)	$ (25,389)	$ (57,330)	$ (65,489)

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5

IO Biotech, Inc. 10-Q